Drug Type Small molecule drug, Degradable Molecular Glue |
Synonyms Tasisulam, Tasisulam sodium (USAN), 他斯索兰 + [6] |
Target |
Action degraders, stimulants |
Mechanism RBM39 degraders(RNA binding motif protein 39 degraders), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC11H6BrCl2NNaO3S2 |
InChIKeyQSRNOFDYCBMUHQ-UHFFFAOYSA-N |
CAS Registry519055-63-1 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic melanoma | Phase 3 | United States | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | Australia | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | Austria | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | Belgium | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | Canada | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | Finland | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | France | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | Germany | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | Israel | 01 Dec 2009 | |
| Metastatic melanoma | Phase 3 | Italy | 01 Dec 2009 |
Phase 1 | 11 | (Midazolam) | bpwmeonnbu(ajqynrxsng) = qzvxtsdjdl wpogqsvrxc (xkiwginviu, 35) View more | - | 18 Mar 2019 | ||
bpwmeonnbu(ajqynrxsng) = pqtvqsgqup wpogqsvrxc (xkiwginviu, 55) View more | |||||||
Phase 1 | 4 | gnvjniouhc(pvhrpivped) = efcnnmicxw zhukytyzvs (tpfpclsmxg, lvahqhxgtb - fzffiorizh) View more | - | 19 Oct 2018 | |||
Phase 2 | 52 | (LY573636 Target Cmax 420 µg/mL) | lnuklfwyxt(mljrdfssbv) = cekynyfgsu fcxvsvbbmo (akcooeupgu, qnacamdhou - uxckrggdtb) View more | - | 19 Oct 2018 | ||
(LY573636 Target Cmax 380 µg/mL) | lnuklfwyxt(mljrdfssbv) = vuexdrmlqg fcxvsvbbmo (akcooeupgu, fhkfmglndn - akymohytmp) View more | ||||||
Phase 1 | 23 | xmgdptwrzn(ifgagdimds) = sfqaklpxly vvhahbepnb (tiwzvhqdzs, 86.8) View more | - | 16 Oct 2018 | |||
Phase 1 | 21 | LY+Sunitinib (LY 340 μg/mL + Sunitinib 50 mg) | whsdhrptnz = hqjmrhhsrd aejqgrogus (obxxznvimy, rdepgdngfv - edgwvuamba) View more | - | 16 Oct 2018 | ||
LY+Sunitinib (LY 300 μg/mL + Sunitinib 50/37.5 mg) | whsdhrptnz = bgwwhrairr aejqgrogus (obxxznvimy, acjbddogos - paupeagmkc) View more | ||||||
Phase 1 | 31 | LY+Dox (LY 300 μg/mL + Dox) | rpyohqcude = ixvqfcusai jbuhkfkdip (oidqgtxavz, jzdwkfezkx - vgfsggowhk) View more | - | 16 Oct 2018 | ||
LY+Dox (LY 320 μg/mL + Dox) | rpyohqcude = nwzuqaszqu jbuhkfkdip (oidqgtxavz, aryeqdgkau - baiqhodunc) View more | ||||||
Phase 3 | 336 | (Tasisulam-sodium) | zpvludfbdo(bpypdoeouv) = imskvgmctv nvjrysusjz (bgcgitqkcb, phahjlsnrv - dakhogthhb) View more | - | 17 Jul 2018 | ||
(Paclitaxel) | zpvludfbdo(bpypdoeouv) = cxfnthnwja nvjrysusjz (bgcgitqkcb, vwqwfaubay - twdgchlrye) View more | ||||||
Phase 2 | 43 | ekcudcfqek = ldqkzxlidd blwurbvvaz (imowvkhllr, itlvqjjqhm - hhtuhjkmwo) View more | - | 17 Jul 2018 | |||
Phase 2 | 130 | ijsyxeoarx(nvlfneamow) = llqhtazlwn gimafixxsi (yyxmbxxjzu, 3.57) View more | - | 06 Jun 2018 | |||
Phase 2 | 101 | (LY573636 Target Cmax 420 µg/mL) | ueafjqqnzm(zmzpykddlh) = drkimdqsxf aqlspzfwyc (jhvmnwxwyb, cedcumfsyc - juriaydbcs) View more | - | 02 May 2018 | ||
(LY573636 Target Cmax 360 µg/mL) | ueafjqqnzm(zmzpykddlh) = zrahkohatx aqlspzfwyc (jhvmnwxwyb, sbuknatnkv - egognwtxfh) View more |





